Immunological monitoring of anticancer vaccines in clinical trials

References

• Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105:93 - 103; http://dx.doi.org/10.1038/bjc.2011.189; PMID: 21629244
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; http://dx.doi.org/10.1186/1479-5876-10-1; PMID: 22214470
   PubMed Web of Science ®Google Scholar
• Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9:657 - 62; PMID: 12576432
   PubMed Web of Science ®Google Scholar
• Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 2003; 3:12; PMID: 12962476
   PubMedGoogle Scholar
• Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13:902 - 11; http://dx.doi.org/10.1158/1078-0432.CCR-06-2363; PMID: 17289884
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49 - 59; http://dx.doi.org/10.1007/s00262-008-0523-4; PMID: 18446337
   PubMed Web of Science ®Google Scholar
• Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother 2013; 9:1049 - 57; http://dx.doi.org/10.4161/hv.23917; PMID: 23454867
   PubMed Web of Science ®Google Scholar
• FDA’s homepage Vaccines, Blood & Biologics, Cellular & Gene Therapy Products, Approved Products. Available from http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210012.htm
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670 - 9; http://dx.doi.org/10.1002/cncr.24429; PMID: 19536890
   PubMed Web of Science ®Google Scholar
• Randazzo M, Terness P, Opelz G, Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012; 130:2219 - 31; http://dx.doi.org/10.1002/ijc.27332; PMID: 22052568
   PubMed Web of Science ®Google Scholar
• Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, et al, C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145 - 54; http://dx.doi.org/10.1016/S0140-6736(08)60697-2; PMID: 18602688
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC Jr., Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004; 22:403 - 15; http://dx.doi.org/10.1200/JCO.2004.06.043; PMID: 14691123
   PubMed Web of Science ®Google Scholar
• Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res 2006; 12:2337s - 41s; http://dx.doi.org/10.1158/1078-0432.CCR-05-2555; PMID: 16609055
   PubMed Web of Science ®Google Scholar
• Therion Reports Results of Phase 3 PANVAC-VF Trial and Announces Plans for Company Sale. PR Newswire 28 June available from http://www.prnewswire.com/news-releases/therion-reports-results-of-phase-3-panvac-vf-trial-and-announces-plans-for-company-sale-56997582.html
   Google Scholar
• Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25:Suppl 2 B97 - 109; http://dx.doi.org/10.1016/j.vaccine.2007.06.067; PMID: 17916465
   PubMed Web of Science ®Google Scholar
• Oncothyreon Inc. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono. Press release; Mar 23, 2010.
   Google Scholar
• Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009; 27:3036 - 43; http://dx.doi.org/10.1200/JCO.2008.19.8903; PMID: 19414675
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787 - 94; http://dx.doi.org/10.1200/JCO.2010.33.3005; PMID: 21632504
   PubMed Web of Science ®Google Scholar
• Fernandes LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, et al. NGcGM3 Ganglioside: a privileged target for cancer vaccines. Clinical and Development Immunology 2010; 2010: 814397; dx.doi.org/10.1155/2010/814397
   Google Scholar
• Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D’addario G, Coens C, Rome LS, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23:6854 - 64; http://dx.doi.org/10.1200/JCO.2005.17.186; PMID: 16192577
   PubMed Web of Science ®Google Scholar
• Gilliam AD, Watson SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther 2007; 7:397 - 404; http://dx.doi.org/10.1517/14712598.7.3.397; PMID: 17309331
   PubMed Web of Science ®Google Scholar
• OncoTherapy Science, Inc. Press release. Feb 29, 2012.
   Google Scholar
• Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, et al, C-100-21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008; 26:955 - 62; http://dx.doi.org/10.1200/JCO.2007.11.9941; PMID: 18281670
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr., Verboom P, Groot MT, Bonsel GJ, Meijer CJ, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005; 23:2379 - 87; http://dx.doi.org/10.1016/j.vaccine.2005.01.015; PMID: 15755632
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008; 8:839 - 44; http://dx.doi.org/10.1517/14712598.8.6.839; PMID: 18476795
   PubMed Web of Science ®Google Scholar
• Pharmexa stops one of two Phase III trials. Drugs.com May 13, 2008 available from http://www.drugs.com/news/pharmexa-stops-one-two-phase-iii-trials-8180.html
   Google Scholar
• Butts CA, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski MJ, et al. START: A Phase III study of L-BLP25 cancer immunotherapy for unresectable Stage III non-small cell lung cancer. J Clin Oncol 2013; 31:suppl; abstr 7500
   Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894 - 903; PMID: 11099318
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003; 13:401 - 7; http://dx.doi.org/10.1016/j.semcancer.2003.09.003; PMID: 15001158
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463 - 82; http://dx.doi.org/10.1097/00000658-199210000-00010; PMID: 1417196
   PubMed Web of Science ®Google Scholar
• Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol 2006; 24:3107 - 12; http://dx.doi.org/10.1200/JCO.2005.04.4289; PMID: 16754937
   PubMed Web of Science ®Google Scholar
• Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma. J Immunother 2010; 33:178 - 84; http://dx.doi.org/10.1097/CJI.0b013e3181bfcea1; PMID: 20145546
   PubMed Web of Science ®Google Scholar
• Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res 1999; 5:1319 - 23; PMID: 10389914
   PubMed Web of Science ®Google Scholar
• Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20:4225 - 31; http://dx.doi.org/10.1200/JCO.2002.11.151; PMID: 12377966
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr., Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15:2359 - 70; PMID: 9196151
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22:4717 - 24; http://dx.doi.org/10.1200/JCO.2004.06.003; PMID: 15483014
   PubMed Web of Science ®Google Scholar
• Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42:303 - 9; http://dx.doi.org/10.1007/s002620050287; PMID: 8706053
   PubMed Web of Science ®Google Scholar
• Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, et al, Theratope® Study Group. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011; 16:1092 - 100; http://dx.doi.org/10.1634/theoncologist.2010-0307; PMID: 21572124
   PubMed Web of Science ®Google Scholar
• Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ. An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 2012; 41:374 - 9; http://dx.doi.org/10.1097/MPA.0b013e31822ade7e; PMID: 22228104
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610 - 8; http://dx.doi.org/10.1200/JCO.2010.30.5425; PMID: 21245428
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009; 27:18s (suppl; abstr2)
   Google Scholar
• Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma. Expert Opin Biol Ther 2007; 7:113 - 22; http://dx.doi.org/10.1517/14712598.7.1.113; PMID: 17150023
   PubMed Web of Science ®Google Scholar
• Shuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission. ASCO2009 Annual Meeting.
   Google Scholar